Losartan potassium 是一种血管紧张素 II 受体 1 型 (AT1)拮抗剂，能够与血管紧张素 II 与 AT1 的结合竞争,其IC50=20 nM。

Losartan, an Angiotensin II Receptor Blocker, selectively and competitively blocks the binding of angiotensin II to the angiotensin I (AT1) receptor.

Losartan competes with the binding of angiotensin II to AT1 receptors. The concentration that inhibits 50% of the binding of angiotensin II (IC50) is 20 nM[1]. Losartan (40?μM) affects ISC but prevents the effect of ANGII on ISC[2]. Losartan significantly reduces Ang II-mediated cell proliferation in endometrial cancer cells. The combination of losartan and anti-miR-155 has a significantly greater antiproliferative effect compared to each drug alone[3].

An MTT assay is used to measure cell proliferation and viability. For the assay, 5000 cells in 200?μL media per well are seeded in a 96 well plate. After overnight incubation to allow for cell attachment, the medium is removed by suction. MTT at 1?mg/mL concentration in serum-free medium is added and then incubated for 4?h at 37°C. After removal of MTT solution, 100?μL of DMSO is added to dissolve formazan crystals. Absorbance at 570?nm and at 600?nm as a reference is then measured using a microplate reader. The difference in absorbance is thus relative to the extent of cell survival.

124750-99-8

C22H22ClKN6O

461.01

DuP-753 potassium;DuP 753;MK 954;洛沙坦钾;氯沙坦钾

DMSO:46.1 mg/mL (100 mM)
H2O:46.1 mg/mL (100 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years